Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2015
16th World Conference on Lung Cancer
Access to all presentations that occur during the 16th World Conference on Lung Cancer in Denver, Colorado
Presentation Date(s):- September 6 - 9, 2015
- Total Presentations: 2499
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
-
+
MTE 06 - Survivorship After Combined Modality Therapy (Imaging, Salvage Therapy) (Ticketed Session)
- Type: Meet the Expert (Ticketed Session)
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 2
- Coordinates: 9/07/2015, 07:00 - 08:00, 102+104+106
-
+
MTE06.01 - Curative Radiotherapy for Local or Locoregional Disease
07:00 - 07:30 | Author(s): Y. Nagata
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MTE06.02 - Survivorship After Combined Modality Therapy (Imaging, Salvage Therapy)
07:30 - 08:00 | Author(s): J.K. Salama
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE 07 - Pharmacologic and Non-Pharmacologic Management of Dyspnea (Ticketed Session)
- Type: Meet the Expert (Ticketed Session)
- Track: Palliative and Supportive Care
- Presentations: 1
- Coordinates: 9/07/2015, 07:00 - 08:00, 108+110+112
-
+
MTE07.01 - Pharmacologic and Non-Pharmacologic Management of Dyspnea
07:00 - 08:00 | Author(s): A. Molasiotis
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE 08 - Tobacco Control: What Do the Experts Do? (Ticketed Session)
- Type: Meet the Expert (Ticketed Session)
- Track: Prevention and Tobacco Control
- Presentations: 2
- Coordinates: 9/07/2015, 07:00 - 08:00, 702+704+706
-
+
MTE08.01 - Tobacco Control: What Do the Experts Do?
07:00 - 07:30 | Author(s): E.R. Gritz
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MTE08.02 - Tobacco Control: What Do the Experts Do?
07:30 - 08:00 | Author(s): E. Stone
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE 09 - Treatment of Advanced SCLC Including Second Line (Ticketed Session)
- Type: Meet the Expert (Ticketed Session)
- Track: Small Cell Lung Cancer
- Presentations: 2
- Coordinates: 9/07/2015, 07:00 - 08:00, 708+710+712
-
+
MTE09.01 - Treatment of Advanced SCLC Including Second Line
07:00 - 07:30 | Author(s): T.K. Owonikoko
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MTE09.02 - Treatment of Advanced SCLC Including Second Line
07:30 - 08:00 | Author(s): C. Zhou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE 10 - Subsolid Nodules: What the Clinicians Need to Know / Clinical Workup of CT Detected Nodules (Ticketed Session)
- Type: Meet the Expert (Ticketed Session)
- Track: Screening and Early Detection
- Presentations: 2
- Coordinates: 9/07/2015, 07:00 - 08:00, 703
-
+
MTE10.01 - Subsolid Nodules: What the Clinicians Need to Know
07:00 - 07:30 | Author(s): K. Garg
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MTE10.02 - Clinical Workup of CT Detected Nodules
07:30 - 08:00 | Author(s): R. Munden
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MTE 11 - Mediastinal Tumors Including Thymic Tumors, Lymphoma, Germ-Cell Tumors: Biology, Diagnosis and Treatment (Ticketed Session)
- Type: Meet the Expert (Ticketed Session)
- Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
- Presentations: 3
- Coordinates: 9/07/2015, 07:00 - 08:00, 201+203
-
+
MTE11.01 - Mediastinal Tumors Including Thymic Tumors, Lymphoma, Germ-Cell Tumors: Biology, Diagnosis and Treatment
07:00 - 07:20 | Author(s): L. Einhorn
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MTE11.02 - Mediastinal Tumors Including Thymic Tumors, Lymphoma, Germ-Cell Tumors: Biology, Diagnosis and Treatment
07:20 - 07:40 | Author(s): G.J. Riely
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MTE11.03 - Mediastinal Tumors Including Thymic Tumors, Lymphoma, Germ-Cell Tumors: Biology, Diagnosis and Treatment
07:40 - 08:00 | Author(s): E. Ruffini
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
PLEN 01 - Lung Cancer Prevention and Screening
- Type: Plenary
- Track: Plenary
- Presentations: 4
- Moderators:C. Dresler
- Coordinates: 9/07/2015, 08:15 - 09:45, Plenary Hall (Bellco Theatre)
-
+
Introduction
08:15 - 08:20
- Abstract
No abstract available for this presentation
-
+
PLEN01.01 - Lung Cancer Screening
08:20 - 08:50 | Author(s): C. Berg
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PLEN01.02 - Epidemiology of Lung Cancer/Smoking in the World
08:50 - 09:20 | Author(s): D. Christiani
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PLEN01.03 - Smoking by Lung Cancer Patients: Clinical, Biologic and Behavioral Considerations
09:20 - 09:50 | Author(s): G. Warren
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 87
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.01-001 - Pembrolizumab for Advanced NSCLC: Patterns of Response and Progression
09:30 - 09:30 | Author(s): J.H. Lee
- Abstract
Loading... -
+
P1.01-002 - Response Evaluation and Predictors in NSCLC During Treatment with AntiPD-L1
09:30 - 09:30 | Author(s): A. Bearz
- Abstract
Loading... -
+
P1.01-003 - Co-Expression of Programmed Death Ligand-1 (PD-L1) and CD3 in Patients with EGFR Mutant NSCLC Treated with EGFR Tyrosine Kinase Inhibitors (TKI)
09:30 - 09:30 | Author(s): R. Soo
- Abstract
Loading... -
+
P1.01-004 - Updated Results and Efficacy Analysis According to EGFR Mutation Subtypes for Gefitinib plus Carboplatin and S-1 of the Phase II Trial
09:30 - 09:30 | Author(s): A. Tamiya
- Abstract
Loading... -
+
P1.01-005 - Early versus Late Brain Metastases in Wild Type and Mutation Positive EGFR Patients
09:30 - 09:30 | Author(s): R. Yuan
- Abstract
Loading... -
+
P1.01-006 - Targeted Drug Selection for Advanced NSCLC Treatment
09:30 - 09:30 | Author(s): J. Ni
- Abstract
Loading... -
+
P1.01-007 - Treatment with EGFR-TKIs in Non Small Cell Lung Cancer Patients. The Impact of EGFR Mutations
09:30 - 09:30 | Author(s): T. Garcia Manrique
- Abstract
Loading... -
+
P1.01-008 - Second Line Erlotinib for NSCLC Patients with EGFR Mutation: Our Experience
09:30 - 09:30 | Author(s): S. Crvenkova
- Abstract
Loading... -
+
P1.01-009 - Combination of Angiogenesis Inhibitor and EGFR-TKIs in Advanced NSCLC Patients Who Developed Acquired Resistance
09:30 - 09:30 | Author(s): X. Song
- Abstract
Loading... -
+
P1.01-010 - Development of Skin Rash within the First Week Is a Potential Surrogate Marker of Effect in Afatinib for EGFR Mutant NSCLC
09:30 - 09:30 | Author(s): K. Kudo
- Abstract
Loading... -
+
P1.01-011 - Response to Erlotinib in Metastatic Lung Adenocarcinoma with a Rare Double Epidermal Growth Factor Receptor (EGFR) Mutation
09:30 - 09:30 | Author(s): S.H.R. Jafri
- Abstract
Loading... -
+
P1.01-012 - Kinase Domain Mutation Positive Lung Cancers Are Sensitive to Intrapleural Perfusion with Hyperthermic Chemotherapy (IPHC) Complete Treatment
09:30 - 09:30 | Author(s): L. Yu
- Abstract
Loading... -
+
P1.01-013 - EGFR Mutations and Targeted Treatment Reverse the Bad Prognosis of Stage IV NSCLC Associated to Liver Metastasis
09:30 - 09:30 | Author(s): E. Castanon
- Abstract
Loading... -
+
P1.01-014 - Long Term Clinical Benefit of EGFR wt in Advanced NSCLC Patients Treated for Long Time with Salvage Erlotinib. A Retrospective Analysis
09:30 - 09:30 | Author(s): A. Kotsakis
- Abstract
Loading... -
+
P1.01-015 - Clinical-Pathological and Survival Analysis of Patients with Advanced NSCLC and EGFR Mutation Treated With a Drug Therapy Anti-T790M
09:30 - 09:30 | Author(s): J. Corral
- Abstract
Loading... -
+
P1.01-016 - Treatment Outcomes among Elderly Lung Cancer Patients > 65 Years following Clinical Use of EGFR Tyrosine Kinase Inhibitor
09:30 - 09:30 | Author(s): W. Lim
- Abstract
Loading... -
+
P1.01-017 - Two Cases of NSCLC with EGFR Exon 20 Insertions with Major Clinical Response to Cetuximab-Containing Therapies
09:30 - 09:30 | Author(s): C.M. Vanderbilt
- Abstract
Loading... -
+
P1.01-018 - Response Rate and Outcomes in Crizotinib Treated Advanced ALK-Positive NSCLC Patients
09:30 - 09:30 | Author(s): K.L. Davis
- Abstract
Loading... -
+
P1.01-019 - Czech Experience with Crizotinib in the Personalized Treatment of NSCLC
09:30 - 09:30 | Author(s): V. Kolek
- Abstract
Loading... -
+
P1.01-020 - Symptoms of Bone and Liver Metastases in Patients with ALK+ Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): A. Guerin
- Abstract
Loading... -
+
P1.01-021 - Crizotinib Efficacy in ALK-Positive Advanced NSCLC Chinese Patients
09:30 - 09:30 | Author(s): S. Cui
- Abstract
Loading... -
+
P1.01-022 - Radiologic Features of Advanced ALK-Rearranged Lung Cancer
09:30 - 09:30 | Author(s): K. Hisakane
- Abstract
Loading... -
+
P1.01-023 - Discrepancy of ALK Status in Lung Adenocarcinoma Subtypes According to the IALSC/ATS/ERS Classification in Chinese Patients
09:30 - 09:30 | Author(s): S. Lu
- Abstract
Loading... -
+
P1.01-024 - Case Report of a Patient with Non-Small Cell Cancer Treated in Two Consecutive Randomized Clinical Trilas. Safety of Imaging Procedures
09:30 - 09:30 | Author(s): E. Chmielowska
- Abstract
Loading... -
+
P1.01-025 - Radical Resection for Supraclavicular Lymph Node Metastasis (N3-Stage IIIB) Adenocarcinoma of the Lung
09:30 - 09:30 | Author(s): J. Zhang
- Abstract
Loading... -
+
P1.01-026 - Post-Treatment Effects of Lung Cancer on Spinal Fracture
09:30 - 09:30 | Author(s): M.O. Tagbarha
- Abstract
Loading... -
+
P1.01-027 - Prognostic Impact of Cytological Fluid Tumor Markers in Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): A. Cho
- Abstract
Loading... -
+
P1.01-028 - Pathological Characteristics of Lung Cancer Patients in Colombian Coffe Zone
09:30 - 09:30 | Author(s): G. Rojas
- Abstract
Loading... -
+
P1.01-029 - Dutch Radiotherapy Lung Audit: Results of 2014
09:30 - 09:30 | Author(s): J. Belderbos
- Abstract
Loading... -
+
P1.01-030 - Curable Bulky T4 Right Lower Lobe Tumours Invading Diaphragm and Liver: A Distinct Entity?
09:30 - 09:30 | Author(s): N. O'Rourke
- Abstract
Loading... -
+
P1.01-031 - Feasibility of Median Sternotomy Approach for Locally Advanced Lung Cancer
09:30 - 09:30 | Author(s): H. Sato
- Abstract
Loading... -
+
P1.01-032 - Surgical Resection for Lung Adenocarcinoma after Afatinib Treatment
09:30 - 09:30 | Author(s): H. Suzuki
- Abstract
Loading... -
+
P1.01-033 - Multiple Organ Metastasis Could Be Identified as Poor Prognostic Factors for NSCLC
09:30 - 09:30 | Author(s): Z. Zhang
- Abstract
Loading... -
+
P1.01-034 - Is There A "Physician Effect" in Medical Oncology?
09:30 - 09:30 | Author(s): H. Jonker
- Abstract
Loading... -
+
P1.01-035 - Clinico-Epidemiological Features and Survival Outcome in Patients with NSCLC: Ain Shams Clinical Oncology Department 5-Year Data
09:30 - 09:30 | Author(s): A.A. Nagy
- Abstract
Loading... -
+
P1.01-036 - RFA for Palliative Treatment of NSCLC Rib Painful Metastasis: Experience in 12 Patients
09:30 - 09:30 | Author(s): H. Mu
- Abstract
Loading... -
+
P1.01-037 - Successful Treatment of Non-Small Cell Lung Cancer with Erlotinib throughout Pregnancy
09:30 - 09:30 | Author(s): Y. Ji
- Abstract
Loading... -
+
P1.01-038 - Endosonographic vs Surgical Staging for Mediastinal Nodal Staging of Lung Cancer: A Systematic Review
09:30 - 09:30 | Author(s): P. Balakrishnan
- Abstract
Loading... -
+
P1.01-039 - Lung Cancer in Kidney Transplant Recipients: A Case-Control Retrospective Study of 30 Patients
09:30 - 09:30 | Author(s): C.R. Gazaniol
- Abstract
Loading... -
+
P1.01-040 - Determining Completeness of Case Ascertainment to the Victorian Lung Cancer Registry: A Quantitative Case Finding Audit
09:30 - 09:30 | Author(s): R. Stirling
- Abstract
Loading... -
+
P1.01-041 - Prognostic Significance of CT Emphysema Score in Patients with Advanced Squamous Cell Carcinoma of the Lung
09:30 - 09:30 | Author(s): Y.S. Kim
- Abstract
Loading... -
+
P1.01-042 - Maintenance Therapy with Pemetrexed after Induction Therapy with Pemetrexed plus Cisplatin for Advanced Pulmonary Adenocarcinoma
09:30 - 09:30 | Author(s): H. Yum
- Abstract
Loading... -
+
P1.01-043 - Prognostic Factors in the First-Line Chemotherapy of Advanced Non-Squamous Non-Small Cell Lung Cancer Patients with Performance Status 2
09:30 - 09:30 | Author(s): S. Hosokawa
- Abstract
Loading... -
+
P1.01-044 - Cost-Effectiveness of Chemotherapy Based on the Tumor Genetic Profile in Elderly Patients with Advanced Non-Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): F. Capano
- Abstract
Loading... -
+
P1.01-045 - Drug Fever After Cancer Chemotherapy Is Most Commonly Observed on Post-Treatment Days 3-4
09:30 - 09:30 | Author(s): M. Fukuda
- Abstract
Loading... -
+
P1.01-046 - Characteristics of Complete Remission Cases in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): T. Aoki
- Abstract
Loading... -
+
P1.01-047 - Pemetrexed in Treating Advanced NSCLC
09:30 - 09:30 | Author(s): M. Olivera
- Abstract
Loading... -
+
P1.01-048 - Cost-Effectiveness of Pemetrexed for Advanced Non-Squamous Non-Small Cell Lung Cancer (nsNSCLC) in Patients Treated in a Spanish Institution
09:30 - 09:30 | Author(s): X. Mielgo Rubio
- Abstract
Loading... -
+
P1.01-049 - Feasibility of Cisplatin plus Etoposide for Non-Small Cell Lung Cancer Associated with Interstitial Lung Disease on Chest Computed Tomography
09:30 - 09:30 | Author(s): M. Yamaguchi
- Abstract
Loading... -
+
P1.01-050 - Clinical Features of Non-Squamous Non-Small-Cell Lung Cancer Patients Treated with Long-Term Pemetrexed
09:30 - 09:30 | Author(s): K. Hirai
- Abstract
Loading... -
+
P1.01-051 - Efficiency of Nab-Paclitaxel as a Late Phase Chemotherapy for NSCLC
09:30 - 09:30 | Author(s): M. Higuchi
- Abstract
Loading... -
+
P1.01-052 - Retreatment with Platinum-Based Regimen for Patients with Metastatic NSCLC Is a Reasonable Therapy
09:30 - 09:30 | Author(s): R.L. Mitchell
- Abstract
Loading... -
+
P1.01-053 - Thiol - Disulfide Ratio (TDR) in Blood as a Predictive in Vitro Test for Individualized Targeted Therapy Choice in Patients with Advanced NSCLC
09:30 - 09:30 | Author(s): O.O. Obodnikov
- Abstract
Loading... -
+
P1.01-054 - To Analyse the Efficacy and Toxicity Profile of Continuation Maintenance Pemetrexed in Advanced NSCLC: An Indian Data
09:30 - 09:30 | Author(s): U. Batra
- Abstract
Loading... -
+
P1.01-055 - Prognostic Impact of KRAS Mutational Status in Patients with Advanced Lung Adenocarcinoma Receiving First-Line Cytotoxic Chemotherapy
09:30 - 09:30 | Author(s): A. Desai
- Abstract
Loading... -
+
P1.01-056 - A Prospective Audit on Toxicity for Platinum-Based Chemotherapy in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC): A West of Scotland Analysis
09:30 - 09:30 | Author(s): C.W. Ali
- Abstract
Loading... -
+
P1.01-057 - Gemcitabine plus Platinum versus Other Platinum Doublets in Squamous NSCLC
09:30 - 09:30 | Author(s): G.V.V. Scagliotti
- Abstract
Loading... -
+
P1.01-058 - Impact of Low-Grade Toxicity on Lung Cancer Patient Willingness to Undergo Treatment with Novel Agents
09:30 - 09:30 | Author(s): E.H. Castellanos
- Abstract
Loading... -
+
P1.01-059 - Steps to Improve NSCLC Patient Outcomes Utilizing Mobile Apps - Survey Findings
09:30 - 09:30 | Author(s): C.J. Langer
- Abstract
Loading... -
+
P1.01-060 - Value Based Health Care Analysis for Lung Cancer Patients
09:30 - 09:30 | Author(s): B. Van Den Borne
- Abstract
Loading... -
+
P1.01-061 - The Chicago Thoracic Oncology Database Consortium: A Multi-Site Database Initiative
09:30 - 09:30 | Author(s): B.M. Won
- Abstract
Loading... -
+
P1.01-062 - Rash as a Marker for the Efficacy of Necitumumab in the SQUIRE Study
09:30 - 09:30 | Author(s): P. Bonomi
- Abstract
Loading... -
+
P1.01-063 - Efficacy and Safety of Erlotinib in Squamous Cell Lung Cancer
09:30 - 09:30 | Author(s): M. Jakopovic
- Abstract
Loading... -
+
P1.01-064 - A Phase II Study of Gemcitabine-Cisplatin plus Necitumumab for Stage IV Sq-NSCLC
09:30 - 09:30 | Author(s): J. Corral
- Abstract
Loading... -
+
P1.01-065 - Bevacizumab Combined with Chemotherapy in the Treatment of Advanced NSCLC Patients
09:30 - 09:30 | Author(s): H. Tao
- Abstract
Loading... -
+
P1.01-066 - Maintenance Bevacizumab after Chemotherapy with Bevacizumab in First Line Treatment of Lung Cancer. A Single Institution Experience
09:30 - 09:30 | Author(s): M. Gamaz Bensaou
- Abstract
Loading... -
+
P1.01-067 - Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-Stage NSCLC
09:30 - 09:30 | Author(s): O. Fiala
- Abstract
Loading... -
+
P1.01-068 - Randomized Trial of Maintenance Chemotherapy Versus SBRT plus Maintenance Chemotherapy for Advanced NSCLC - Feasibility and Early Outcomes
09:30 - 09:30 | Author(s): Z. Wardak
- Abstract
Loading... -
+
P1.01-069 - Reasons for Discontinuation of Treatment with Bevacizumab in Patients with Non-Progressing NSCLC - Retrospective Study
09:30 - 09:30 | Author(s): P. Berzinec
- Abstract
Loading... -
+
P1.01-070 - KRAS Mutations: Does It Mean No Erlotinib?
09:30 - 09:30 | Author(s): M. Dias
- Abstract
Loading... -
+
P1.01-071 - Long-Term Tolerability Among IRESSA Clinical Access Program (ICAP) Participants in the United States (US)
09:30 - 09:30 | Author(s): P.A. Bunn, Jr
- Abstract
Loading... -
+
P1.01-072 - Targeted Delivery of a Synthetic microRNA-Based Mimic to Treat Thoracic Cancers
09:30 - 09:30 | Author(s): G. Reid
- Abstract
Loading... -
+
P1.01-073 - MET and Invasive Function in NSCLC
09:30 - 09:30 | Author(s): T. Mirzapoiazova
- Abstract
Loading... -
+
P1.01-074 - Phase III Study of WBRT with or without Erlotinib for Brain Metastasis NSCLC
09:30 - 09:30 | Author(s): Z. Yang
- Abstract
Loading... -
+
P1.01-075 - Phase III, Randomized, Double-Blind Trial of Bavituximab Plus Docetaxel in Previously Treated Stage IIIb/IV Non-Squamous NSCLC (SUNRISE)
09:30 - 09:30 | Author(s): D.R. Spigel
- Abstract
Loading... -
+
P1.01-076 - TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC
09:30 - 09:30 | Author(s): R. Camidge
- Abstract
Loading... -
+
P1.01-077 - First-Line Nivolumab + Nab-Paclitaxel + Carboplatin (C) in Advanced NSCLC
09:30 - 09:30 | Author(s): D. Waterhouse
- Abstract
Loading... -
+
P1.01-078 - Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1-Strong-Positive NSCLC
09:30 - 09:30 | Author(s): J.R. Brahmer
- Abstract
Loading... -
+
P1.01-079 - Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line Therapy for NSCLC
09:30 - 09:30 | Author(s): S. Gadgeel
- Abstract
Loading... -
+
P1.01-080 - Treatment Rationale and Study Design for the Phase 3 JUNIPER Study: Abemaciclib vs Erlotinib in Patients with Stage IV NSCLC and KRAS Mutation
09:30 - 09:30 | Author(s): J.W. Goldman
- Abstract
Loading... -
+
P1.01-081 - Patritumab Plus Erlotinib in EGFR Wild-Type Advanced Non-Small Cell Lung Cancer: A 2-Part Phase 3 Study (HER3-Lung)
09:30 - 09:30 | Author(s): W.L. Akerley
- Abstract
Loading... -
+
P1.01-082 - A Phase III Study of MEDI4736 (M) an Anti-PD-L1 Antibody ± Tremelimumab (T), vs Standard of Care (SoC), in Patients with Advanced NSCLC (ARCTIC)
09:30 - 09:30 | Author(s): D. Planchard
- Abstract
Loading... -
+
P1.01-083 - Phase 2 Study of MEDI4736 in Patients with PD-L1+ Locally Advanced or Metastatic Stage IIIb-IV NSCLC Treated with ≥ 2 Prior Regimens (ATLANTIC)
09:30 - 09:30 | Author(s): M.C. Garassino
- Abstract
Loading... -
+
P1.01-084 - A Phase 2 Study of TH-4000 in Patients with EGFR Mutant, T790M-Negative, Advanced NSCLC Progressing on an EGFR TKI
09:30 - 09:30 | Author(s): S.V. Liu
- Abstract
Loading... -
+
P1.01-085 - A Multicenter Phase 1B Study of Ceritinib plus Nivolumab in Patients with ALK+ NSCLC
09:30 - 09:30 | Author(s): A. Shaw
- Abstract
Loading... -
+
P1.01-086 - TIGER-3: A Phase 3 Open-Label, Randomized Study of Rociletinib vs Chemotherapy in NSCLC
09:30 - 09:30 | Author(s): J.C. Yang
- Abstract
Loading... -
+
P1.01-087 - A Phase I Study of Chloroquine with Carboplatin and Gemcitabine in Advanced Solid Tumors and NSCLC
09:30 - 09:30 | Author(s): N. Abdel Karim
- Abstract
Loading...
-
+
P1.02 - Poster Session/ Treatment of Localized Disease – NSCLC
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 39
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.02-001 - Predictive Factors of Distant and Local Recurrence in Patients with Surgically Resected Stage 1 NSCLC
09:30 - 09:30 | Author(s): S. Mizuguchi
- Abstract
Loading... -
+
P1.02-002 - Interstitial Lung Disease (ILD) Associated Cancer Genesis Is Noble Predictor for Patients with Non-Small Cell Lung Cancer and ILD
09:30 - 09:30 | Author(s): R. Miyata
- Abstract
Loading... -
+
P1.02-003 - Accuracy of Clinical and Pathologic Staging of Non-Small Cell Lung Cancer in a Residency Education Program
09:30 - 09:30 | Author(s): M.J. Almarashda
- Abstract
Loading... -
+
P1.02-004 - Accurate Assessment of Vessel Invasion Using D2-40 and Victoria Blue Predicts Recurrence in Patients with Pathological Stage I NSCLC
09:30 - 09:30 | Author(s): S. Okada
- Abstract
Loading... -
+
P1.02-005 - Impact of Postoperative Complications on Cancer Recurrence following Lung Cancer Surgery
09:30 - 09:30 | Author(s): T. Nojiri
- Abstract
Loading... -
+
P1.02-006 - Visceral Pleural Invasion Was Common in Larger (> 2 cm) Ground Glass Nodules, but Showed No Aggressive Prognostic Impact
09:30 - 09:30 | Author(s): L. Zhao
- Abstract
Loading... -
+
P1.02-007 - The Histologic Subtype of Lung Adenocarcinoma Should Not Deter Sublobar Resection for Patients with Clinical Stage IA Lung Cancer
09:30 - 09:30 | Author(s): M. Kamel
- Abstract
Loading... -
+
P1.02-008 - Diagnostic Molecular Testing in Multiple Lung Cancers
09:30 - 09:30 | Author(s): J. Naidoo
- Abstract
Loading... -
+
P1.02-009 - Prognostic Value of New IASLC/ATS/RES Lung Adenocarcinoma Classification on Dominate Tumor in Synchronous Multiple Primary Adenocarcinomas
09:30 - 09:30 | Author(s): C. Huang
- Abstract
Loading... -
+
P1.02-010 - What Is the Difference between Lung Cancer and Infectious Lung Disease in Predicted Postoperative Pulmonary Function after Pneumonectomy?
09:30 - 09:30 | Author(s): T. Nakagawa
- Abstract
Loading... -
+
P1.02-011 - The Discordance of Two Major Diagnostic Criteria for Chronic Obstructive Pulmonary Disease Affects Lung Cancer Prognosis after Resection
09:30 - 09:30 | Author(s): M. Yotsukura
- Abstract
Loading... -
+
P1.02-012 - Study for Prognostic Impact of Tumor Volume Instead of Tumor Size for T Staging in NSCLCancer
09:30 - 09:30 | Author(s): D. Kim
- Abstract
Loading... -
+
P1.02-013 - The New Interventional Technique by Photodynamic Therapy Using Composite-Type Optical Fiberscope of 1.0 mm in Diameter
09:30 - 09:30 | Author(s): J. Usuda
- Abstract
Loading... -
+
P1.02-014 - Predictive Factors of Postoperative Acute Exacerbation of Interstitial Pneumonia for Patients with Lung Cancer
09:30 - 09:30 | Author(s): H. Yukiue
- Abstract
Loading... -
+
P1.02-015 - Pathological Variables in Resected NSCLC Tumours: Predictors of Survival?
09:30 - 09:30 | Author(s): M. Evison
- Abstract
Loading... -
+
P1.02-016 - Prevalence of Preoperative DVT in Japanese Patients Who Underwent Thoracic Surgery by Intensive Screeng
09:30 - 09:30 | Author(s): T. Takemoto
- Abstract
Loading... -
+
P1.02-017 - Complications after Lobectomy or Segmentectomy for cT1aN0M0 Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): T. Ohtsuka
- Abstract
Loading... -
+
P1.02-018 - Needlescopic Lobectomy and Segmentectomy for Primary Lung Cancer: Less Invasive Surgery Using Fine Scope and Forceps
09:30 - 09:30 | Author(s): M. Tajiri
- Abstract
Loading... -
+
P1.02-019 - Effectiveness of Touch Cytology on the Staple Line in the Assessment of Resection Margins for Pulmonary Malignant Tumors
09:30 - 09:30 | Author(s): R. Nakahara
- Abstract
Loading... -
+
P1.02-020 - Physiological Assessment in Thoracic Surgery for High Risk Patients with Lung Cancer; How Do International Guidelines Compare?
09:30 - 09:30 | Author(s): H. Al-Najjar
- Abstract
Loading... -
+
P1.02-021 - The Feasibility of Fluorescence Image-Guided Surgery for Pulmonary Nodules
09:30 - 09:30 | Author(s): H.K. Kim
- Abstract
Loading... -
+
P1.02-022 - Sleeve Lobectomy Is a Safe and Effective Oncologic Procedure: A Single Center Experience over Three Decades
09:30 - 09:30 | Author(s): L.C. Silva Corten
- Abstract
Loading... -
+
P1.02-023 - The Role of Selective EBUS-TBNA Mediastinal Sampling in Early Lung Cancer
09:30 - 09:30 | Author(s): R. Burrah
- Abstract
Loading... -
+
P1.02-024 - Conditional Survival after Surgical Treatment of Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): T. Fukui
- Abstract
Loading... -
+
P1.02-025 - Complete VATS Resection and Reconstruction of Carina and Trachea for Malignant or Benign Disease
09:30 - 09:30 | Author(s): J. He
- Abstract
Loading... -
+
P1.02-026 - For NSCLC with T3 (Central) Disease, Sleeve Lobectomy or Pneumonectomy?
09:30 - 09:30 | Author(s): Q. Ma
- Abstract
Loading... -
+
P1.02-027 - Thoracoscopic Segmentectomy of Pulmonary Nodules after Computed Tomography-Assisted Bronchoscopic Metallic Coil Marking
09:30 - 09:30 | Author(s): T. Miyoshi
- Abstract
Loading... -
+
P1.02-028 - Surgical Resection for Sarcomatoid Carcinoma of the Lung
09:30 - 09:30 | Author(s): T. Kilani
- Abstract
Loading... -
+
P1.02-029 - Long and Short-Term Predictors of Outcome in Elderly Patients (≥ 75 Years) Undergoing Lobectomy for Stage I Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): T. Eguchi
- Abstract
Loading... -
+
P1.02-030 - Effectiveness of Extended Bilateral Superior Mediastinal Lymph Node Dissection Through a Median Sternotomy in Patients with Left NSCLC
09:30 - 09:30 | Author(s): T. Yokota
- Abstract
Loading... -
+
P1.02-031 - Wedge Resection for NSCLC: Does Minimally Invasive Surgery Warrant the Maximum Advantage?
09:30 - 09:30 | Author(s): P. Bertoglio
- Abstract
Loading... -
+
P1.02-032 - Randomized Feasibility Study of S-1 for Adjuvant Chemotherapy in Completely-Resected Stage IA Non-Small-Cell Lung Cancer (SLCG 0701)
09:30 - 09:30 | Author(s): N. Okumura
- Abstract
Loading... -
+
P1.02-033 - Pemetrexed plus Platinum as Adjuvant Therapy in Patients with Resected Lung Adenocarcinoma and Exploratory Biomarkers Analysis
09:30 - 09:30 | Author(s): B. Wang
- Abstract
Loading... -
+
P1.02-034 - Lung v5 Does Not Predict for Lung Toxicity after Fixed-Beam Intensity Modulated Radiotherapy (IMRT)
09:30 - 09:30 | Author(s): C. Chan
- Abstract
Loading... -
+
P1.02-035 - Radiographic Changes in Lung of Patients Treated with Stereotactic Ablative Body Radiation Therapy and the Dosimetric Correlations
09:30 - 09:30 | Author(s): F. Wang
- Abstract
Loading... -
+
P1.02-036 - Peripheral Blood Immunophenotype Changes Following Thoracic Stereotactic Ablative Radiotherapy
09:30 - 09:30 | Author(s): M.E. Daly
- Abstract
Loading... -
+
P1.02-037 - Thoracic Radiation-Induced Pleural Effusion and Risk Factors in Patients with Lung Cancer
09:30 - 09:30 | Author(s): J. Zhao
- Abstract
Loading... -
+
P1.02-038 - A Comparison of Stereotactic Body Radiation Therapy vs. No Treatment for Patients with Early-Stage Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): S.S. Jeppesen
- Abstract
Loading... -
+
P1.02-039 - Stereotactic Radiotherapy as Salvage Treatment after Stereotactic Radiotherapy or after Operated Non-Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): T. Schytte
- Abstract
Loading...
-
+
P1.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC
- Type: Poster
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 31
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.03-001 - Survival of the NSCLC Patients with Clinical Stage IIIA Disease with N2 Involvement: Case-Control Study with Emphasis on Treatment Modality
09:30 - 09:30 | Author(s): S. Andersson
- Abstract
Loading... -
+
P1.03-002 - Surgery in Subclassified Stage IIIA-N2 Lung Cancer Improves Survival
09:30 - 09:30 | Author(s): H. Hofmann
- Abstract
Loading... -
+
P1.03-003 - A Clinicopathological Study of Resected Small-Sized Non-Small Cell Lung Cancer 2 cm or Less in Diameter with N2 Lymph Node Metastasis
09:30 - 09:30 | Author(s): Y. Kato
- Abstract
Loading... -
+
P1.03-004 - Occult Primary Non-Small Cell Lung Cancer with Mediastinal Lymph Node Involvement
09:30 - 09:30 | Author(s): P.B. Romesser
- Abstract
Loading... -
+
P1.03-005 - Bilobectomy for Lung Cancer: Postoperative Results, and Long-Term Outcomes
09:30 - 09:30 | Author(s): M. Rahouma
- Abstract
Loading... -
+
P1.03-006 - Survival Analysis of 121 Cases of Stage III A (N2) Non-Small Cell Lung Cancer Treated with Surgery Resection
09:30 - 09:30 | Author(s): L. Dai
- Abstract
Loading... -
+
P1.03-007 - Prognosis of Microscopic Residual Disease (R1) at Different Resection Margins and Efficacy of Adjuvant Therapy
09:30 - 09:30 | Author(s): M. Chiba
- Abstract
Loading... -
+
P1.03-008 - Weekly Carboplatin/Gemcitabine + Concurrent Thoracic RT Followed by Consolidation Carboplatin/Gemcitabine for Inoperable Stage III NSCLC
09:30 - 09:30 | Author(s): M. Domine
- Abstract
Loading... -
+
P1.03-009 - Integration of Chemoradiotherapy in a Single Facility: Impact on Outcomes for Locally Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): H.S. Park
- Abstract
Loading... -
+
P1.03-010 - Adjuvant Chemotherapy plus Radiotherapy is Superior to Chemotherapy in Surgically Treated IIIA N2 Non-Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): X. Xu
- Abstract
Loading... -
+
P1.03-011 - Standard Pre-Hydration May Compromise Treatment Outcome of CRT with Low-Dose Cisplatin
09:30 - 09:30 | Author(s): E. Aalbersberg
- Abstract
Loading... -
+
P1.03-012 - Combined Effects of SAHA and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in NSCLC
09:30 - 09:30 | Author(s): S. Zhang
- Abstract
Loading... -
+
P1.03-013 - Clinical Characteristics and Survival in Stage IIIA NSCLC Patients Treated with Neoadjuvant Chemotherapy and Surgery
09:30 - 09:30 | Author(s): N. Duma
- Abstract
Loading... -
+
P1.03-014 - Is Concomitant Chemoradiotherapy Feasible for Patients with NSCLC Stage III A/B?
09:30 - 09:30 | Author(s): F.S. Van Der Meer
- Abstract
Loading... -
+
P1.03-015 - Safety and Effectiveness of Chemo-Radiotherapy with Weekly Nab Paclitaxel plus Carboplatin in Locally Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): T. Sawa
- Abstract
Loading... -
+
P1.03-016 - Clinical Outcome of Hybrid-Volumetric Arc Therapy (H-VMAT) for Advanced Inoperable Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): O.S.H. Chan
- Abstract
Loading... -
+
P1.03-017 - Radiation Dose-Related Lymphopenia as an Outcome Predictor in Stage III NSCLC Patients Treated with Chemoradiation
09:30 - 09:30 | Author(s): N. Hashemi Sadraei
- Abstract
Loading... -
+
P1.03-018 - International Patterns of Radiotherapy Practice for Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): S.K. Vinod
- Abstract
Loading... -
+
P1.03-019 - NTCP-Models for Esophagitis with Dose-Differentiated-Radiotherapy (DART-Bid)
09:30 - 09:30 | Author(s): F. Zehentmayr
- Abstract
Loading... -
+
P1.03-020 - IMRT Improves Survival in Locally Advanced NSCLC (LA-NSCLC) Receiving Definitive Radiotherapy: A Population Based Time-Trend Analysis
09:30 - 09:30 | Author(s): J. Wang
- Abstract
Loading... -
+
P1.03-021 - Lung Damage Quantification on CT Scans Strengthens Radiation-Induced Lung Toxicity Prediction Models
09:30 - 09:30 | Author(s): G. Defraene
- Abstract
Loading... -
+
P1.03-022 - The Effect of Adaptive Planning on Target and Critical Structures During Radiation Treatment for Locally Advanced Lung Cancer
09:30 - 09:30 | Author(s): H.B. Caglar
- Abstract
Loading... -
+
P1.03-023 - Changes in Pulmonary Function after Stereotactic Body Radiotherapy and after Surgery for Stage I and II Non-Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): L. Alberts
- Abstract
Loading... -
+
P1.03-024 - Comparison of Prognosis Between Patients with Solitary Lung Adenocarcinoma and With Multiple Primary Cancers Including Lung Adenocarcinoma
09:30 - 09:30 | Author(s): E. Yi
- Abstract
Loading... -
+
P1.03-025 - Relation of Visceral Pleura Invasion with Hilar Lymph Node Involvement and Survival in Primary Lung Cancer
09:30 - 09:30 | Author(s): S. Tanju
- Abstract
Loading... -
+
P1.03-026 - Prognostic Value of Pre-Treatment Neutrophil:Lymphocyte Ratio and Platelet:Lymphocyte Ratio in Stage III NSCLC
09:30 - 09:30 | Author(s): K.H. Kang
- Abstract
Loading... -
+
P1.03-027 - Factors Predicting Lymph Node Metastasis in Resected Lung Adenocarcinoma of 2cm or Smaller
09:30 - 09:30 | Author(s): J. Hung
- Abstract
Loading... -
+
P1.03-028 - Multicenter Study of the Usefulness of FDG-PET as a Predictor of the Clinicopathological Characteristics and Prognosis of Lung Cancer
09:30 - 09:30 | Author(s): N. Ikeda
- Abstract
Loading... -
+
P1.03-029 - Obesity Is Associated with Long-Term Improved Survival in Definitively Treated Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)
09:30 - 09:30 | Author(s): V.K. Lam
- Abstract
Loading... -
+
P1.03-030 - Marital Status Is Strongly Prognostic and Associated with More Favorable Nutritional Status in Locally Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): J.L. Feliciano
- Abstract
Loading... -
+
P1.03-031 - Concurrent Chemoradiotherapy Using Advanced Radiotherapy Technologies for Inoperable Stage III Non-Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): J.S.K. Au
- Abstract
Loading...
first
prev
